{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:49:13Z","timestamp":1777294153516,"version":"3.51.4"},"publisher-location":"Chichester, UK","reference-count":39,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd003715.pub2","type":"reference-entry","created":{"date-parts":[[2005,1,26]],"date-time":"2005-01-26T15:50:44Z","timestamp":1106754644000},"source":"Crossref","is-referenced-by-count":71,"title":["Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease"],"prefix":"10.1002","author":[{"given":"Anthony K","family":"Akobeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Gardener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,1,24]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD003715.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2036.1990.tb00449.x","article-title":"Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group","volume":"4","author":"Anonymous","year":"1990","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1002\/14651858.CD003715.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00004836-199504000-00008","article-title":"A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission","volume":"20","author":"Arber","year":"1995","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD003715.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0016-5085(93)90411-5","article-title":"Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Inflammatoires Digestives (GETAID)","volume":"104","author":"Gendre","year":"1993","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003715.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/gut.49.4.552","article-title":"Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study","volume":"49","author":"Mahmud","year":"2001","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD003715.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0016-5085(92)90822-G","article-title":"Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group","volume":"103","author":"Prantera","year":"1992","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003715.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0016-5085(97)70117-3","article-title":"A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group","volume":"112","author":"Sutherland","year":"1997","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD003715.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2036.1995.tb00438.x","article-title":"Mesalazine (Mesasal\/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn' s disease","volume":"9","author":"Thomson","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1002\/14651858.CD003715.pub2-BIB8|cit8","first-page":"200","article-title":"5-aminosalicylic acid in the prevention of relapses of Crohn's disease in remission: a long-term study","volume":"11","author":"Bresci","year":"1991","journal-title":"Int J Clin Pharmacol Res"},{"issue":"4","key":"10.1002\/14651858.CD003715.pub2-BIB9|cit9","first-page":"133","article-title":"Long-term therapy with 5-aminosalicylic acid in Crohn's disease: is it useful? Our four years experience","volume":"14","author":"Bresci","year":"1994","journal-title":"Int J Clin Pharmacol Res"},{"issue":"1","key":"10.1002\/14651858.CD003715.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF01308338","article-title":"Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease","volume":"37","author":"Brignola","year":"1992","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1002\/14651858.CD003715.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/gast.1997.v113.pm9352848","article-title":"Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables","volume":"113","author":"Camma","year":"1997","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD003715.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1046\/j.1365-2036.1997.00212.x","article-title":"Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease","volume":"11","author":"Franchis","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1002\/14651858.CD003715.pub2-BIB13|cit13","first-page":"251","article-title":"Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders","volume":"29","author":"Gendre","year":"1993","journal-title":"Ann. Gastroenterol Hepatol"},{"issue":"9","key":"10.1002\/14651858.CD003715.pub2-BIB14|cit14","first-page":"1343","article-title":"Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group","volume":"88","author":"Hanauer","year":"1993","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1002\/14651858.CD003715.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1053\/gast.1996.v110.pm8608877","article-title":"Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives","volume":"110","author":"Modigliani","year":"1996","journal-title":"Gastroenterology"},{"issue":"797","key":"10.1002\/14651858.CD003715.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/pgmj.68.797.189","article-title":"Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?","volume":"68","author":"Nakshabendi","year":"1992","journal-title":"Postgrad Med J"},{"issue":"8","key":"10.1002\/14651858.CD003715.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/gut.35.8.1081","article-title":"Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot sutdy in the maintenance treatment of Crohn's ileocolitis","volume":"35","author":"Schreiber","year":"1994","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003715.pub2-BIB18|cit18","unstructured":"Alderson P Green S Higgens JPT Assessment of study quality. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]; Section 6. In: The Cochrane Library, Issue 1, 2004 Chichester, UK: John Wiley & Sons, Ltd"},{"issue":"8044","key":"10.1002\/14651858.CD003715.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(77)90831-5","article-title":"An experiment to determine the active therapeutic moiety of sulphasalazine","volume":"2","author":"Azad Khan","year":"1977","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003715.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2036.17.s2.20.x","article-title":"Review article: maintenance treatment of Crohn's disease","volume":"17 Suppl 2","author":"Biancone","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1002\/14651858.CD003715.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM197309062891001","article-title":"Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype","volume":"289","author":"Das","year":"1973","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1002\/14651858.CD003715.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators","volume":"342","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"issue":"12 Suppl","key":"10.1002\/14651858.CD003715.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.amjgastroenterol.2003.11.002","article-title":"Maintenance therapy for inflammatory bowel disease","volume":"98","author":"Feagan","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"9317","key":"10.1002\/14651858.CD003715.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003715.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2036.2004.02048.x","article-title":"Review article: aminosalicylates in inflammatory bowel disease","volume":"20 Suppl 4","author":"Hanauer","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1002\/14651858.CD003715.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"26","key":"10.1002\/14651858.CD003715.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJM198012253032602","article-title":"Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease","volume":"303","author":"Klotz","year":"1980","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1002\/14651858.CD003715.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1572-0241.2003.04010.x","article-title":"Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries","volume":"99","author":"Lichtenstein","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1002\/14651858.CD003715.pub2-BIB29|cit29","first-page":"692","article-title":"Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis","volume":"89","author":"Messori","year":"1994","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD003715.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/gut.28.2.196","article-title":"Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract","volume":"28","author":"Myers","year":"1987","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD003715.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"issue":"12 Suppl","key":"10.1002\/14651858.CD003715.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.amjgastroenterol.2003.10.007","article-title":"Evidence-based treatment algorithm for mild to moderate Crohn's disease","volume":"98","author":"Sandborn","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1002\/14651858.CD003715.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1002\/14651858.CD003715.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/gut.13.4.278","article-title":"Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects","volume":"13","author":"Schroder","year":"1972","journal-title":"Gut"},{"issue":"12","key":"10.1002\/14651858.CD003715.pub2-BIB35|cit35","first-page":"2116","article-title":"Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis","volume":"89","author":"Steinhart","year":"1994","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1002\/14651858.CD003715.pub2-BIB36|cit36","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000301","article-title":"Corticosteroids for maintenance of remission in Crohn's disease","author":"Steinhart","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003715.pub2-BIB37|cit37","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","author":"Sutherland","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003715.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.0954-6820.1942.tb06841.x","article-title":"Salazopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation","volume":"110","author":"Svartz","year":"1942","journal-title":"Acta Med Scand"},{"issue":"7","key":"10.1002\/14651858.CD003715.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/gut.21.7.632","article-title":"Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine","volume":"21","author":"Hees","year":"1980","journal-title":"Gut"}],"updated-by":[{"DOI":"10.1002\/14651858.cd003715.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T00:00:00Z","timestamp":1475020800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003715.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T05:53:56Z","timestamp":1705816436000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003715.pub2"}},"subtitle":[],"editor":[{"given":"Anthony K","family":"Akobeng","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2005,1,24]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003715.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD003715.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2005,1,24]]}}}